Long-term efficacy and safety after corneal collagen crosslinking in pediatric patients: Three-year follow-up.

Abstract

PURPOSE:

To evaluate the effectiveness of standard corneal collagen crosslinking for children with progressive keratoconus.

METHODS:

Prospective study including 26 eyes of 26 patients younger than 18 years old with progressive keratoconus at Oftalmosalud Instituto de Ojos, Lima, Peru. Standard epi-off corneal crosslinking was performed in all eyes between January 2012 and January 2013. Pre- and postoperative evaluation (at 3 years) included uncorrected and best-corrected visual acuity and Scheimpflug analysis. Crosslinking failure was defined as an increase in maximum keratometry (Kmax) of more than 1 diopter after 1 year or more.

RESULTS:

Mean uncorrected visual acuity improvement was 0.24 LogMAR (p = 0.07) and mean best-corrected visual acuity improvement was 0.18 LogMAR (p = 0.01). None of the eyes lost more than one line in the best-corrected visual acuity. Four eyes (15.38%) lost two lines in the uncorrected visual acuity at 3 years postoperative. Mean steeper keratometry improvement was 1.14 diopters (p = 0.60). Progression rate was 23.07%.

CONCLUSION:

Standard epi-off corneal collagen crosslinking is safe and effective to halt the progression of the keratoconus with significant improvement in the best-corrected visual acuity at 3-year follow-up.

• Authors: Maria A Henriquez, Sandra Villegas, Mirel Rincon, Carmen Maldonado, Luis Izquierdo Jr
• Journal: European journal of ophthalmology (Eur J Ophthalmol) Vol. 28 Issue 4 Pg. 415-418 (Jul 2018) ISSN: 1724-6016 [Electronic] United States
• PMID: 29564931 (Publication Type: Journal Article)

Chemical References

• Cross-Linking Reagents
• Photosensitizing Agents
• Collagen
• Riboflavin

Topics

• Adolescent
• Child
• Collagen (therapeutic use)
• Cornea (diagnostic imaging)
• Corneal Pachymetry
• Corneal Topography
• Cross-Linking Reagents (therapeutic use)
• Disease Progression
• Female
• Follow-Up Studies
• Humans
• Keratoconus (drug therapy, pathology)
• Male
• Photochemotherapy (methods)
• Photosensitizing Agents (therapeutic use)
• Prospective Studies
• Riboflavin (therapeutic use)
• Time Factors
• Ultraviolet Rays
• Visual Acuity